IL17RA and psoriasis: Although monoclonal antibodies that specifically target IL23, IL17, and IL17 receptor A (IL17RA) significantly improve psoriasis symptoms [1], the therapy cannot eliminate pathogenic T cells, which subsequently contribute to a relapse of psoriasis through again provoking keratinocytes [14,15].